Candel Therapeutics (CADL) vs Nuvectis Pharma (NVCT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Nuvectis Pharma (NVCT) has outperformed Candel Therapeutics (CADL) over the past year, gaining 223.1% versus a gain of 53.3%. Candel Therapeutics is the larger company by market cap ($739.2 million vs $657.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CADL | NVCT |
|---|---|---|
| Share price | $9.66 | $20.13 |
| Market cap | $739.17M | $657.12M |
| 1-day change | -1.63% | -0.79% |
| YTD return | +70.97% | +166.62% |
| 1-year return | +53.33% | +223.11% |
| 5-year return | -1.73% | — |
| EPS (TTM) | $-1.46 | $-1.31 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.00 | $29.28 |
| 52-week low | $4.35 | $5.55 |
| Distance from 52-week high | -31.00% | -31.24% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +125.16% | +75.86% |
| Average volume | 1.21M | 215.43K |
| Shares outstanding | 76.52M | 32.64M |
| Employees | 55 | 16 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NVCT has outperformed CADL by 169.8 percentage points over the past year.
About Candel Therapeutics
CADL stock →Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for cancer patients. It develops CAN-2409, which is in Phase 2a clinical trials for the treatment of prostate cancer; and Phase 2a clinical trials for the treatment of non-small cell lung cancer (NSCLC).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 55 employees
About Nuvectis Pharma
NVCT stock →Nuvectis Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious conditions of unmet medical need in oncology. The company is developing NXP900, a small molecule drug candidate, which is in Phase 1b clinical trial that inhibits the proto-oncogene c-Src and YES1 kinases for treating solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 16 employees
CADL vs NVCT FAQ
Which is bigger, Candel Therapeutics or Nuvectis Pharma?
Candel Therapeutics (CADL) is larger, with a market capitalization of $739.17M compared with $657.12M for Nuvectis Pharma (NVCT).
Which stock has performed better over the past year, CADL or NVCT?
NVCT returned +223.11% over the past 12 months, compared with +53.33% for CADL (price return, excluding dividends). Past performance does not predict future results.
Are Candel Therapeutics and Nuvectis Pharma in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Candel Therapeutics and Biotechnology: Pharmaceutical Preparations for Nuvectis Pharma.